nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—lung cancer	0.221	1	CbGaD
Carfilzomib—ABCB1—Topotecan—lung cancer	0.0354	0.136	CbGbCtD
Carfilzomib—ABCB1—Gefitinib—lung cancer	0.0324	0.124	CbGbCtD
Carfilzomib—ABCB1—Vinorelbine—lung cancer	0.0249	0.0958	CbGbCtD
Carfilzomib—ABCB1—Crizotinib—lung cancer	0.0198	0.0762	CbGbCtD
Carfilzomib—ABCB1—Gemcitabine—lung cancer	0.0194	0.0745	CbGbCtD
Carfilzomib—ABCB1—Erlotinib—lung cancer	0.0191	0.0735	CbGbCtD
Carfilzomib—ABCB1—Paclitaxel—lung cancer	0.0175	0.0673	CbGbCtD
Carfilzomib—ABCB1—Irinotecan—lung cancer	0.0173	0.0664	CbGbCtD
Carfilzomib—ABCB1—Vinblastine—lung cancer	0.0154	0.059	CbGbCtD
Carfilzomib—ABCB1—Cisplatin—lung cancer	0.0141	0.0541	CbGbCtD
Carfilzomib—ABCB1—Etoposide—lung cancer	0.0138	0.0532	CbGbCtD
Carfilzomib—ABCB1—Docetaxel—lung cancer	0.0127	0.0486	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—lung cancer	0.00944	0.0363	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—lung cancer	0.00914	0.0351	CbGbCtD
Carfilzomib—PSMB10—respiratory system—lung cancer	0.00716	0.0857	CbGeAlD
Carfilzomib—PSMB2—mammary gland—lung cancer	0.00521	0.0624	CbGeAlD
Carfilzomib—PSMB10—lung—lung cancer	0.0038	0.0455	CbGeAlD
Carfilzomib—PSMB8—bronchus—lung cancer	0.0038	0.0455	CbGeAlD
Carfilzomib—PSMB1—respiratory system—lung cancer	0.00356	0.0426	CbGeAlD
Carfilzomib—PSMB2—respiratory system—lung cancer	0.00347	0.0416	CbGeAlD
Carfilzomib—PSMB8—trachea—lung cancer	0.00341	0.0408	CbGeAlD
Carfilzomib—PSMB5—bronchus—lung cancer	0.00335	0.0402	CbGeAlD
Carfilzomib—PSMB5—trachea—lung cancer	0.00301	0.0361	CbGeAlD
Carfilzomib—PSMB1—bronchus—lung cancer	0.00293	0.0351	CbGeAlD
Carfilzomib—PSMB2—bronchus—lung cancer	0.00286	0.0342	CbGeAlD
Carfilzomib—PSMB5—cardiac atrium—lung cancer	0.00283	0.0339	CbGeAlD
Carfilzomib—PSMB8—bone marrow—lung cancer	0.0027	0.0324	CbGeAlD
Carfilzomib—PSMB1—trachea—lung cancer	0.00263	0.0315	CbGeAlD
Carfilzomib—PSMB10—lymph node—lung cancer	0.0026	0.0311	CbGeAlD
Carfilzomib—PSMB2—trachea—lung cancer	0.00257	0.0307	CbGeAlD
Carfilzomib—PSMB1—cardiac atrium—lung cancer	0.00247	0.0296	CbGeAlD
Carfilzomib—PSMB8—lung—lung cancer	0.00245	0.0293	CbGeAlD
Carfilzomib—PSMB2—cardiac atrium—lung cancer	0.00241	0.0289	CbGeAlD
Carfilzomib—PSMB5—bone marrow—lung cancer	0.00239	0.0286	CbGeAlD
Carfilzomib—PSMB5—lung—lung cancer	0.00216	0.0259	CbGeAlD
Carfilzomib—PSMB1—bone marrow—lung cancer	0.00209	0.025	CbGeAlD
Carfilzomib—PSMB2—bone marrow—lung cancer	0.00204	0.0244	CbGeAlD
Carfilzomib—PSMB1—lung—lung cancer	0.00189	0.0226	CbGeAlD
Carfilzomib—PSMB2—lung—lung cancer	0.00184	0.0221	CbGeAlD
Carfilzomib—PSMB8—lymph node—lung cancer	0.00167	0.0201	CbGeAlD
Carfilzomib—PSMB5—lymph node—lung cancer	0.00148	0.0177	CbGeAlD
Carfilzomib—PSMB10—Vinblastine—Vinorelbine—lung cancer	0.00144	0.251	CbGdCrCtD
Carfilzomib—PSMB1—lymph node—lung cancer	0.00129	0.0155	CbGeAlD
Carfilzomib—PSMB2—lymph node—lung cancer	0.00126	0.0151	CbGeAlD
Carfilzomib—Ritonavir—ABCG2—lung cancer	0.00112	0.37	CrCbGaD
Carfilzomib—PSMB8—Podofilox—Teniposide—lung cancer	0.00107	0.187	CbGdCrCtD
Carfilzomib—Ritonavir—CYP2E1—lung cancer	0.000892	0.293	CrCbGaD
Carfilzomib—PSMB2—Azacitidine—Gemcitabine—lung cancer	0.000715	0.125	CbGdCrCtD
Carfilzomib—PSMB8—Vincristine—Vinorelbine—lung cancer	0.000681	0.119	CbGdCrCtD
Carfilzomib—PSMB8—Vinorelbine—Vinblastine—lung cancer	0.000636	0.111	CbGdCrCtD
Carfilzomib—PSMB8—Podofilox—Etoposide—lung cancer	0.000636	0.111	CbGdCrCtD
Carfilzomib—Lopinavir—ABCB1—lung cancer	0.000557	0.183	CrCbGaD
Carfilzomib—PSMB8—Vincristine—Vinblastine—lung cancer	0.000544	0.0952	CbGdCrCtD
Carfilzomib—ABCB1—respiratory system—lung cancer	0.000531	0.00636	CbGeAlD
Carfilzomib—Ritonavir—ABCB1—lung cancer	0.000468	0.154	CrCbGaD
Carfilzomib—ABCB1—epithelium—lung cancer	0.000444	0.00531	CbGeAlD
Carfilzomib—ABCB1—trachea—lung cancer	0.000392	0.0047	CbGeAlD
Carfilzomib—ABCB1—bone marrow—lung cancer	0.000311	0.00373	CbGeAlD
Carfilzomib—ABCB1—lung—lung cancer	0.000282	0.00338	CbGeAlD
Carfilzomib—Hypoaesthesia—Etoposide—lung cancer	0.000236	0.00105	CcSEcCtD
Carfilzomib—Anorexia—Vinorelbine—lung cancer	0.000234	0.00104	CcSEcCtD
Carfilzomib—Back pain—Gemcitabine—lung cancer	0.000234	0.00104	CcSEcCtD
Carfilzomib—Hypoaesthesia—Paclitaxel—lung cancer	0.000232	0.00102	CcSEcCtD
Carfilzomib—Neutropenia—Docetaxel—lung cancer	0.000231	0.00102	CcSEcCtD
Carfilzomib—Nausea—Teniposide—lung cancer	0.00023	0.00102	CcSEcCtD
Carfilzomib—Anaemia—Irinotecan—lung cancer	0.00023	0.00102	CcSEcCtD
Carfilzomib—Oedema peripheral—Paclitaxel—lung cancer	0.000229	0.00101	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—lung cancer	0.000229	0.00101	CcSEcCtD
Carfilzomib—Body temperature increased—Topotecan—lung cancer	0.000227	0.00101	CcSEcCtD
Carfilzomib—Body temperature increased—Erlotinib—lung cancer	0.000225	0.000995	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Vinorelbine—lung cancer	0.000224	0.000991	CcSEcCtD
Carfilzomib—Anaemia—Gemcitabine—lung cancer	0.000224	0.00099	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—lung cancer	0.000223	0.000985	CcSEcCtD
Carfilzomib—Leukopenia—Irinotecan—lung cancer	0.000222	0.000984	CcSEcCtD
Carfilzomib—Pneumonia—Docetaxel—lung cancer	0.000221	0.000978	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—lung cancer	0.00022	0.000975	CcSEcCtD
Carfilzomib—Dyspnoea—Vinorelbine—lung cancer	0.000219	0.00097	CcSEcCtD
Carfilzomib—Muscle spasms—Cisplatin—lung cancer	0.000217	0.00096	CcSEcCtD
Carfilzomib—Cough—Irinotecan—lung cancer	0.000217	0.000959	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Docetaxel—lung cancer	0.000217	0.000959	CcSEcCtD
Carfilzomib—Leukopenia—Gemcitabine—lung cancer	0.000217	0.000958	CcSEcCtD
Carfilzomib—Renal failure—Docetaxel—lung cancer	0.000216	0.000956	CcSEcCtD
Carfilzomib—Cardiac disorder—Paclitaxel—lung cancer	0.000216	0.000956	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Docetaxel—lung cancer	0.000215	0.000953	CcSEcCtD
Carfilzomib—Hypertension—Irinotecan—lung cancer	0.000215	0.000949	CcSEcCtD
Carfilzomib—Decreased appetite—Vinorelbine—lung cancer	0.000214	0.000946	CcSEcCtD
Carfilzomib—Chills—Etoposide—lung cancer	0.000213	0.000942	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—lung cancer	0.000213	0.000941	CcSEcCtD
Carfilzomib—Asthenia—Vinblastine—lung cancer	0.000212	0.000939	CcSEcCtD
Carfilzomib—Fatigue—Vinorelbine—lung cancer	0.000212	0.000938	CcSEcCtD
Carfilzomib—Cough—Gemcitabine—lung cancer	0.000211	0.000934	CcSEcCtD
Carfilzomib—Constipation—Vinorelbine—lung cancer	0.00021	0.00093	CcSEcCtD
Carfilzomib—Pain—Vinorelbine—lung cancer	0.00021	0.00093	CcSEcCtD
Carfilzomib—Hypertension—Gemcitabine—lung cancer	0.000209	0.000924	CcSEcCtD
Carfilzomib—Chills—Paclitaxel—lung cancer	0.000209	0.000924	CcSEcCtD
Carfilzomib—Anaemia—Cisplatin—lung cancer	0.000209	0.000922	CcSEcCtD
Carfilzomib—Asthenia—Topotecan—lung cancer	0.000206	0.000912	CcSEcCtD
Carfilzomib—Arthralgia—Gemcitabine—lung cancer	0.000206	0.000912	CcSEcCtD
Carfilzomib—Asthenia—Erlotinib—lung cancer	0.000204	0.000903	CcSEcCtD
Carfilzomib—Diarrhoea—Vinblastine—lung cancer	0.000202	0.000896	CcSEcCtD
Carfilzomib—Leukopenia—Cisplatin—lung cancer	0.000202	0.000893	CcSEcCtD
Carfilzomib—Infection—Irinotecan—lung cancer	0.000201	0.000891	CcSEcCtD
Carfilzomib—Back pain—Etoposide—lung cancer	0.0002	0.000884	CcSEcCtD
Carfilzomib—Muscle spasms—Etoposide—lung cancer	0.000199	0.000879	CcSEcCtD
Carfilzomib—Thrombocytopenia—Irinotecan—lung cancer	0.000199	0.000878	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—lung cancer	0.000198	0.000876	CcSEcCtD
Carfilzomib—Diarrhoea—Topotecan—lung cancer	0.000197	0.00087	CcSEcCtD
Carfilzomib—Hypoaesthesia—Docetaxel—lung cancer	0.000196	0.000869	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—lung cancer	0.000196	0.000868	CcSEcCtD
Carfilzomib—Infection—Gemcitabine—lung cancer	0.000196	0.000868	CcSEcCtD
Carfilzomib—Back pain—Paclitaxel—lung cancer	0.000196	0.000867	CcSEcCtD
Carfilzomib—Dizziness—Vinblastine—lung cancer	0.000196	0.000866	CcSEcCtD
Carfilzomib—Muscle spasms—Paclitaxel—lung cancer	0.000195	0.000862	CcSEcCtD
Carfilzomib—Diarrhoea—Erlotinib—lung cancer	0.000195	0.000861	CcSEcCtD
Carfilzomib—Body temperature increased—Vinorelbine—lung cancer	0.000194	0.00086	CcSEcCtD
Carfilzomib—Oedema peripheral—Docetaxel—lung cancer	0.000194	0.00086	CcSEcCtD
Carfilzomib—Thrombocytopenia—Gemcitabine—lung cancer	0.000193	0.000856	CcSEcCtD
Carfilzomib—Anorexia—Irinotecan—lung cancer	0.000193	0.000855	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—lung cancer	0.000193	0.000853	CcSEcCtD
Carfilzomib—ABCB1—lymph node—lung cancer	0.000193	0.00231	CbGeAlD
Carfilzomib—Anaemia—Etoposide—lung cancer	0.000191	0.000845	CcSEcCtD
Carfilzomib—Dizziness—Topotecan—lung cancer	0.00019	0.000841	CcSEcCtD
Carfilzomib—Anorexia—Gemcitabine—lung cancer	0.000188	0.000833	CcSEcCtD
Carfilzomib—Vomiting—Vinblastine—lung cancer	0.000188	0.000832	CcSEcCtD
Carfilzomib—Dizziness—Erlotinib—lung cancer	0.000188	0.000832	CcSEcCtD
Carfilzomib—Anaemia—Paclitaxel—lung cancer	0.000187	0.000829	CcSEcCtD
Carfilzomib—Headache—Vinblastine—lung cancer	0.000185	0.00082	CcSEcCtD
Carfilzomib—Leukopenia—Etoposide—lung cancer	0.000185	0.000818	CcSEcCtD
Carfilzomib—Insomnia—Irinotecan—lung cancer	0.000183	0.000811	CcSEcCtD
Carfilzomib—Cardiac disorder—Docetaxel—lung cancer	0.000183	0.00081	CcSEcCtD
Carfilzomib—Infection—Cisplatin—lung cancer	0.000183	0.000809	CcSEcCtD
Carfilzomib—Vomiting—Topotecan—lung cancer	0.000183	0.000808	CcSEcCtD
Carfilzomib—Leukopenia—Paclitaxel—lung cancer	0.000181	0.000802	CcSEcCtD
Carfilzomib—Vomiting—Erlotinib—lung cancer	0.000181	0.0008	CcSEcCtD
Carfilzomib—Dyspnoea—Irinotecan—lung cancer	0.000181	0.0008	CcSEcCtD
Carfilzomib—Cough—Etoposide—lung cancer	0.00018	0.000798	CcSEcCtD
Carfilzomib—Thrombocytopenia—Cisplatin—lung cancer	0.00018	0.000798	CcSEcCtD
Carfilzomib—Headache—Topotecan—lung cancer	0.00018	0.000797	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.00018	0.000796	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—lung cancer	0.000179	0.000791	CcSEcCtD
Carfilzomib—Insomnia—Gemcitabine—lung cancer	0.000179	0.00079	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—lung cancer	0.000178	0.000789	CcSEcCtD
Carfilzomib—Headache—Erlotinib—lung cancer	0.000178	0.000788	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—lung cancer	0.000178	0.000787	CcSEcCtD
Carfilzomib—Chills—Docetaxel—lung cancer	0.000177	0.000783	CcSEcCtD
Carfilzomib—Cough—Paclitaxel—lung cancer	0.000177	0.000782	CcSEcCtD
Carfilzomib—Asthenia—Vinorelbine—lung cancer	0.000176	0.00078	CcSEcCtD
Carfilzomib—Decreased appetite—Irinotecan—lung cancer	0.000176	0.00078	CcSEcCtD
Carfilzomib—Dyspnoea—Gemcitabine—lung cancer	0.000176	0.000779	CcSEcCtD
Carfilzomib—Nausea—Vinblastine—lung cancer	0.000176	0.000777	CcSEcCtD
Carfilzomib—Anorexia—Cisplatin—lung cancer	0.000176	0.000776	CcSEcCtD
Carfilzomib—Hypertension—Paclitaxel—lung cancer	0.000175	0.000774	CcSEcCtD
Carfilzomib—Fatigue—Irinotecan—lung cancer	0.000175	0.000773	CcSEcCtD
Carfilzomib—Pain—Irinotecan—lung cancer	0.000173	0.000767	CcSEcCtD
Carfilzomib—Constipation—Irinotecan—lung cancer	0.000173	0.000767	CcSEcCtD
Carfilzomib—Arthralgia—Paclitaxel—lung cancer	0.000173	0.000763	CcSEcCtD
Carfilzomib—Decreased appetite—Gemcitabine—lung cancer	0.000172	0.00076	CcSEcCtD
Carfilzomib—Nausea—Topotecan—lung cancer	0.000171	0.000755	CcSEcCtD
Carfilzomib—Fatigue—Gemcitabine—lung cancer	0.00017	0.000753	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—lung cancer	0.000169	0.000749	CcSEcCtD
Carfilzomib—Constipation—Gemcitabine—lung cancer	0.000169	0.000747	CcSEcCtD
Carfilzomib—Pain—Gemcitabine—lung cancer	0.000169	0.000747	CcSEcCtD
Carfilzomib—Nausea—Erlotinib—lung cancer	0.000169	0.000747	CcSEcCtD
Carfilzomib—Diarrhoea—Vinorelbine—lung cancer	0.000168	0.000744	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000168	0.000742	CcSEcCtD
Carfilzomib—Infection—Etoposide—lung cancer	0.000168	0.000741	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—lung cancer	0.000167	0.000738	CcSEcCtD
Carfilzomib—Back pain—Docetaxel—lung cancer	0.000166	0.000735	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—lung cancer	0.000166	0.000735	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—lung cancer	0.000165	0.000731	CcSEcCtD
Carfilzomib—Muscle spasms—Docetaxel—lung cancer	0.000165	0.000731	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—lung cancer	0.000165	0.000731	CcSEcCtD
Carfilzomib—Infection—Paclitaxel—lung cancer	0.000164	0.000727	CcSEcCtD
Carfilzomib—Dyspnoea—Cisplatin—lung cancer	0.000164	0.000726	CcSEcCtD
Carfilzomib—Dizziness—Vinorelbine—lung cancer	0.000163	0.000719	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—lung cancer	0.000162	0.000717	CcSEcCtD
Carfilzomib—Thrombocytopenia—Paclitaxel—lung cancer	0.000162	0.000716	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—lung cancer	0.000161	0.000711	CcSEcCtD
Carfilzomib—Body temperature increased—Irinotecan—lung cancer	0.00016	0.000709	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.00016	0.000709	CcSEcCtD
Carfilzomib—Decreased appetite—Cisplatin—lung cancer	0.00016	0.000708	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—lung cancer	0.000159	0.000705	CcSEcCtD
Carfilzomib—Anaemia—Docetaxel—lung cancer	0.000159	0.000702	CcSEcCtD
Carfilzomib—Anorexia—Paclitaxel—lung cancer	0.000158	0.000697	CcSEcCtD
Carfilzomib—Pain—Cisplatin—lung cancer	0.000157	0.000697	CcSEcCtD
Carfilzomib—Vomiting—Vinorelbine—lung cancer	0.000156	0.000692	CcSEcCtD
Carfilzomib—Body temperature increased—Gemcitabine—lung cancer	0.000156	0.000691	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—lung cancer	0.000156	0.000689	CcSEcCtD
Carfilzomib—Headache—Vinorelbine—lung cancer	0.000154	0.000681	CcSEcCtD
Carfilzomib—Leukopenia—Docetaxel—lung cancer	0.000154	0.00068	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000151	0.000667	CcSEcCtD
Carfilzomib—Dyspnoea—Etoposide—lung cancer	0.00015	0.000665	CcSEcCtD
Carfilzomib—Cough—Docetaxel—lung cancer	0.00015	0.000663	CcSEcCtD
Carfilzomib—Insomnia—Paclitaxel—lung cancer	0.00015	0.000662	CcSEcCtD
Carfilzomib—Hypertension—Docetaxel—lung cancer	0.000148	0.000656	CcSEcCtD
Carfilzomib—Dyspnoea—Paclitaxel—lung cancer	0.000147	0.000652	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—lung cancer	0.000147	0.000649	CcSEcCtD
Carfilzomib—Arthralgia—Docetaxel—lung cancer	0.000146	0.000647	CcSEcCtD
Carfilzomib—Nausea—Vinorelbine—lung cancer	0.000146	0.000646	CcSEcCtD
Carfilzomib—Body temperature increased—Cisplatin—lung cancer	0.000146	0.000644	CcSEcCtD
Carfilzomib—Asthenia—Irinotecan—lung cancer	0.000146	0.000644	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—lung cancer	0.000145	0.000643	CcSEcCtD
Carfilzomib—Pain—Etoposide—lung cancer	0.000144	0.000638	CcSEcCtD
Carfilzomib—Constipation—Etoposide—lung cancer	0.000144	0.000638	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—lung cancer	0.000144	0.000636	CcSEcCtD
Carfilzomib—Decreased appetite—Paclitaxel—lung cancer	0.000144	0.000636	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000143	0.000633	CcSEcCtD
Carfilzomib—Fatigue—Paclitaxel—lung cancer	0.000143	0.000631	CcSEcCtD
Carfilzomib—Asthenia—Gemcitabine—lung cancer	0.000142	0.000627	CcSEcCtD
Carfilzomib—Pain—Paclitaxel—lung cancer	0.000141	0.000626	CcSEcCtD
Carfilzomib—Constipation—Paclitaxel—lung cancer	0.000141	0.000626	CcSEcCtD
Carfilzomib—Infection—Docetaxel—lung cancer	0.000139	0.000616	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—lung cancer	0.000139	0.000614	CcSEcCtD
Carfilzomib—Diarrhoea—Irinotecan—lung cancer	0.000139	0.000614	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—lung cancer	0.000138	0.00061	CcSEcCtD
Carfilzomib—Thrombocytopenia—Docetaxel—lung cancer	0.000137	0.000607	CcSEcCtD
Carfilzomib—Diarrhoea—Gemcitabine—lung cancer	0.000135	0.000598	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—lung cancer	0.000135	0.000597	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—lung cancer	0.000134	0.000595	CcSEcCtD
Carfilzomib—Dizziness—Irinotecan—lung cancer	0.000134	0.000593	CcSEcCtD
Carfilzomib—Anorexia—Docetaxel—lung cancer	0.000134	0.000591	CcSEcCtD
Carfilzomib—Body temperature increased—Etoposide—lung cancer	0.000133	0.00059	CcSEcCtD
Carfilzomib—Asthenia—Cisplatin—lung cancer	0.000132	0.000584	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—lung cancer	0.000132	0.000584	CcSEcCtD
Carfilzomib—Body temperature increased—Paclitaxel—lung cancer	0.000131	0.000578	CcSEcCtD
Carfilzomib—Vomiting—Irinotecan—lung cancer	0.000129	0.00057	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000128	0.000565	CcSEcCtD
Carfilzomib—Chills—Methotrexate—lung cancer	0.000128	0.000564	CcSEcCtD
Carfilzomib—Headache—Irinotecan—lung cancer	0.000127	0.000562	CcSEcCtD
Carfilzomib—Insomnia—Docetaxel—lung cancer	0.000127	0.000561	CcSEcCtD
Carfilzomib—Diarrhoea—Cisplatin—lung cancer	0.000126	0.000557	CcSEcCtD
Carfilzomib—Vomiting—Gemcitabine—lung cancer	0.000126	0.000556	CcSEcCtD
Carfilzomib—Dyspnoea—Docetaxel—lung cancer	0.000125	0.000553	CcSEcCtD
Carfilzomib—Headache—Gemcitabine—lung cancer	0.000124	0.000547	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—lung cancer	0.000123	0.000542	CcSEcCtD
Carfilzomib—Decreased appetite—Docetaxel—lung cancer	0.000122	0.000539	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—lung cancer	0.000121	0.000537	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—lung cancer	0.000121	0.000535	CcSEcCtD
Carfilzomib—Fatigue—Docetaxel—lung cancer	0.000121	0.000535	CcSEcCtD
Carfilzomib—Nausea—Irinotecan—lung cancer	0.00012	0.000533	CcSEcCtD
Carfilzomib—Constipation—Docetaxel—lung cancer	0.00012	0.00053	CcSEcCtD
Carfilzomib—Pain—Docetaxel—lung cancer	0.00012	0.00053	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—lung cancer	0.00012	0.00053	CcSEcCtD
Carfilzomib—Asthenia—Paclitaxel—lung cancer	0.000119	0.000525	CcSEcCtD
Carfilzomib—Nausea—Gemcitabine—lung cancer	0.000117	0.000519	CcSEcCtD
Carfilzomib—Vomiting—Cisplatin—lung cancer	0.000117	0.000518	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—lung cancer	0.000115	0.000511	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—lung cancer	0.000114	0.000506	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—lung cancer	0.000114	0.000506	CcSEcCtD
Carfilzomib—Diarrhoea—Paclitaxel—lung cancer	0.000113	0.000501	CcSEcCtD
Carfilzomib—Dizziness—Etoposide—lung cancer	0.000112	0.000493	CcSEcCtD
Carfilzomib—Body temperature increased—Docetaxel—lung cancer	0.000111	0.00049	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—lung cancer	0.000111	0.00049	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—lung cancer	0.00011	0.000489	CcSEcCtD
Carfilzomib—Dizziness—Paclitaxel—lung cancer	0.000109	0.000484	CcSEcCtD
Carfilzomib—Nausea—Cisplatin—lung cancer	0.000109	0.000484	CcSEcCtD
Carfilzomib—Cough—Methotrexate—lung cancer	0.000108	0.000478	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—lung cancer	0.000107	0.000474	CcSEcCtD
Carfilzomib—Headache—Etoposide—lung cancer	0.000106	0.000467	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—lung cancer	0.000105	0.000466	CcSEcCtD
Carfilzomib—Vomiting—Paclitaxel—lung cancer	0.000105	0.000465	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—lung cancer	0.000104	0.000459	CcSEcCtD
Carfilzomib—Headache—Paclitaxel—lung cancer	0.000104	0.000458	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—lung cancer	0.000103	0.000456	CcSEcCtD
Carfilzomib—Asthenia—Docetaxel—lung cancer	0.000101	0.000445	CcSEcCtD
Carfilzomib—Infection—Methotrexate—lung cancer	0.0001	0.000444	CcSEcCtD
Carfilzomib—Nausea—Etoposide—lung cancer	0.0001	0.000443	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—lung cancer	9.91e-05	0.000438	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—lung cancer	9.89e-05	0.000438	CcSEcCtD
Carfilzomib—Nausea—Paclitaxel—lung cancer	9.82e-05	0.000435	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—lung cancer	9.63e-05	0.000426	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—lung cancer	9.6e-05	0.000424	CcSEcCtD
Carfilzomib—Diarrhoea—Docetaxel—lung cancer	9.59e-05	0.000424	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—lung cancer	9.35e-05	0.000414	CcSEcCtD
Carfilzomib—Dizziness—Docetaxel—lung cancer	9.27e-05	0.00041	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—lung cancer	9.26e-05	0.000409	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—lung cancer	9.21e-05	0.000407	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—lung cancer	9.14e-05	0.000404	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—lung cancer	9.13e-05	0.000404	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—lung cancer	9.01e-05	0.000398	CcSEcCtD
Carfilzomib—Vomiting—Docetaxel—lung cancer	8.91e-05	0.000394	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—lung cancer	8.78e-05	0.000389	CcSEcCtD
Carfilzomib—Headache—Docetaxel—lung cancer	8.78e-05	0.000389	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—lung cancer	8.71e-05	0.000385	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—lung cancer	8.69e-05	0.000385	CcSEcCtD
Carfilzomib—Pain—Methotrexate—lung cancer	8.64e-05	0.000382	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—lung cancer	8.57e-05	0.000379	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—lung cancer	8.34e-05	0.000369	CcSEcCtD
Carfilzomib—Nausea—Docetaxel—lung cancer	8.33e-05	0.000368	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—lung cancer	7.99e-05	0.000353	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—lung cancer	7.97e-05	0.000353	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—lung cancer	7.91e-05	0.00035	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—lung cancer	7.8e-05	0.000345	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—lung cancer	7.61e-05	0.000336	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—lung cancer	7.54e-05	0.000334	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—lung cancer	7.48e-05	0.000331	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—lung cancer	7.48e-05	0.000331	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—lung cancer	7.25e-05	0.000321	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—lung cancer	6.92e-05	0.000306	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—lung cancer	6.91e-05	0.000306	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—lung cancer	6.68e-05	0.000296	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—lung cancer	6.42e-05	0.000284	CcSEcCtD
Carfilzomib—Headache—Methotrexate—lung cancer	6.33e-05	0.00028	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—lung cancer	6.28e-05	0.000278	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—lung cancer	6e-05	0.000265	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—lung cancer	5.99e-05	0.000265	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—lung cancer	5.79e-05	0.000256	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—lung cancer	5.56e-05	0.000246	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—lung cancer	5.48e-05	0.000242	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—lung cancer	5.2e-05	0.00023	CcSEcCtD
Carfilzomib—PSMB5—Disease—MAPK3—lung cancer	8.85e-06	4.43e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SRC—lung cancer	8.83e-06	4.42e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOA3—lung cancer	8.81e-06	4.4e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK3—lung cancer	8.73e-06	4.36e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—lung cancer	8.67e-06	4.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—lung cancer	8.67e-06	4.34e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—lung cancer	8.67e-06	4.34e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—lung cancer	8.64e-06	4.32e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MDM2—lung cancer	8.63e-06	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MDM2—lung cancer	8.63e-06	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MDM2—lung cancer	8.63e-06	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—lung cancer	8.61e-06	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—lung cancer	8.61e-06	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—lung cancer	8.61e-06	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—lung cancer	8.61e-06	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—lung cancer	8.61e-06	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—lung cancer	8.61e-06	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—lung cancer	8.6e-06	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RAF1—lung cancer	8.6e-06	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RAF1—lung cancer	8.6e-06	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RAF1—lung cancer	8.6e-06	4.3e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ABCG2—lung cancer	8.57e-06	4.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ADCY1—lung cancer	8.57e-06	4.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—lung cancer	8.56e-06	4.28e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—lung cancer	8.55e-06	4.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—lung cancer	8.54e-06	4.27e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—lung cancer	8.54e-06	4.27e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—lung cancer	8.53e-06	4.27e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—lung cancer	8.52e-06	4.26e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—lung cancer	8.51e-06	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—lung cancer	8.51e-06	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—lung cancer	8.51e-06	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MDM2—lung cancer	8.51e-06	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—lung cancer	8.5e-06	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—lung cancer	8.5e-06	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—lung cancer	8.49e-06	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—lung cancer	8.49e-06	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—lung cancer	8.49e-06	4.24e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—lung cancer	8.48e-06	4.24e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RAF1—lung cancer	8.48e-06	4.24e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—lung cancer	8.44e-06	4.22e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—lung cancer	8.42e-06	4.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—lung cancer	8.42e-06	4.21e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—lung cancer	8.42e-06	4.21e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HPGDS—lung cancer	8.4e-06	4.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO2—lung cancer	8.4e-06	4.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—lung cancer	8.39e-06	4.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—lung cancer	8.39e-06	4.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MTOR—lung cancer	8.39e-06	4.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—lung cancer	8.39e-06	4.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MTOR—lung cancer	8.39e-06	4.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MTOR—lung cancer	8.39e-06	4.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—lung cancer	8.39e-06	4.19e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPP2R1B—lung cancer	8.35e-06	4.18e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—lung cancer	8.3e-06	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MTOR—lung cancer	8.28e-06	4.14e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—lung cancer	8.28e-06	4.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—EP300—lung cancer	8.27e-06	4.14e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—EP300—lung cancer	8.27e-06	4.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—EP300—lung cancer	8.27e-06	4.14e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK3—lung cancer	8.18e-06	4.09e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—EP300—lung cancer	8.16e-06	4.08e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTT1—lung cancer	8.15e-06	4.08e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK3—lung cancer	8.14e-06	4.07e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—lung cancer	8.07e-06	4.04e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—lung cancer	8.07e-06	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—lung cancer	8.07e-06	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—lung cancer	8.07e-06	4.03e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GCLC—lung cancer	8.06e-06	4.03e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2A6—lung cancer	8.06e-06	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—lung cancer	8.04e-06	4.02e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—lung cancer	7.95e-06	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—lung cancer	7.95e-06	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—lung cancer	7.95e-06	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—lung cancer	7.95e-06	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—lung cancer	7.95e-06	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—lung cancer	7.92e-06	3.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—lung cancer	7.91e-06	3.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—lung cancer	7.91e-06	3.96e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—lung cancer	7.91e-06	3.96e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	7.91e-06	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—lung cancer	7.88e-06	3.94e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—lung cancer	7.84e-06	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—lung cancer	7.84e-06	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—lung cancer	7.8e-06	3.9e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—lung cancer	7.78e-06	3.89e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—lung cancer	7.74e-06	3.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—lung cancer	7.72e-06	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—lung cancer	7.72e-06	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—lung cancer	7.72e-06	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—lung cancer	7.71e-06	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—lung cancer	7.71e-06	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—lung cancer	7.71e-06	3.86e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO1—lung cancer	7.64e-06	3.82e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	7.63e-06	3.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—lung cancer	7.61e-06	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—lung cancer	7.6e-06	3.8e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—lung cancer	7.51e-06	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—lung cancer	7.51e-06	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—lung cancer	7.51e-06	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JUN—lung cancer	7.5e-06	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JUN—lung cancer	7.5e-06	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JUN—lung cancer	7.5e-06	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—lung cancer	7.41e-06	3.71e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JUN—lung cancer	7.39e-06	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—lung cancer	7.35e-06	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—lung cancer	7.32e-06	3.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—lung cancer	7.32e-06	3.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—lung cancer	7.32e-06	3.66e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—lung cancer	7.31e-06	3.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—lung cancer	7.31e-06	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—lung cancer	7.31e-06	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—lung cancer	7.31e-06	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—lung cancer	7.3e-06	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—lung cancer	7.3e-06	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—lung cancer	7.3e-06	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—lung cancer	7.27e-06	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—lung cancer	7.27e-06	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—lung cancer	7.27e-06	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—lung cancer	7.25e-06	3.63e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—lung cancer	7.25e-06	3.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—lung cancer	7.25e-06	3.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—lung cancer	7.22e-06	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—lung cancer	7.2e-06	3.6e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—lung cancer	7.19e-06	3.6e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—lung cancer	7.17e-06	3.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—lung cancer	7.15e-06	3.58e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	7.14e-06	3.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—lung cancer	7.01e-06	3.5e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—lung cancer	7.01e-06	3.5e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—lung cancer	7.01e-06	3.5e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EP300—lung cancer	6.92e-06	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EP300—lung cancer	6.92e-06	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EP300—lung cancer	6.92e-06	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—lung cancer	6.91e-06	3.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2E1—lung cancer	6.85e-06	3.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EP300—lung cancer	6.82e-06	3.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NQO1—lung cancer	6.77e-06	3.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—lung cancer	6.76e-06	3.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—lung cancer	6.76e-06	3.38e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—lung cancer	6.76e-06	3.38e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—lung cancer	6.75e-06	3.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—lung cancer	6.73e-06	3.36e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—lung cancer	6.73e-06	3.36e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—lung cancer	6.73e-06	3.36e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—lung cancer	6.72e-06	3.36e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—lung cancer	6.67e-06	3.33e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—lung cancer	6.63e-06	3.32e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—lung cancer	6.6e-06	3.3e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—lung cancer	6.57e-06	3.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—lung cancer	6.55e-06	3.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—lung cancer	6.55e-06	3.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—lung cancer	6.55e-06	3.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—lung cancer	6.53e-06	3.27e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—lung cancer	6.5e-06	3.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—lung cancer	6.49e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—lung cancer	6.49e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—lung cancer	6.49e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—lung cancer	6.47e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—lung cancer	6.47e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—lung cancer	6.47e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—lung cancer	6.47e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—lung cancer	6.47e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—lung cancer	6.47e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—lung cancer	6.47e-06	3.23e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—lung cancer	6.47e-06	3.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—lung cancer	6.47e-06	3.23e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—lung cancer	6.46e-06	3.23e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	6.46e-06	3.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—lung cancer	6.43e-06	3.22e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—lung cancer	6.43e-06	3.22e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—lung cancer	6.43e-06	3.22e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—lung cancer	6.4e-06	3.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—lung cancer	6.38e-06	3.19e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—lung cancer	6.38e-06	3.19e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—lung cancer	6.37e-06	3.19e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—lung cancer	6.34e-06	3.17e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—lung cancer	6.25e-06	3.12e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—lung cancer	6.22e-06	3.11e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK3—lung cancer	6.2e-06	3.1e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK3—lung cancer	6.2e-06	3.1e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK3—lung cancer	6.2e-06	3.1e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—lung cancer	6.12e-06	3.06e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—lung cancer	6.12e-06	3.06e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—lung cancer	6.12e-06	3.06e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK3—lung cancer	6.11e-06	3.06e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—STK11—lung cancer	6.1e-06	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—lung cancer	6.03e-06	3.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—lung cancer	6.03e-06	3.01e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—lung cancer	6.03e-06	3.01e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—lung cancer	6.03e-06	3.01e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—lung cancer	5.98e-06	2.99e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—lung cancer	5.97e-06	2.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—lung cancer	5.97e-06	2.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—lung cancer	5.97e-06	2.99e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—lung cancer	5.95e-06	2.98e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—lung cancer	5.94e-06	2.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—lung cancer	5.9e-06	2.95e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—lung cancer	5.9e-06	2.95e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—lung cancer	5.9e-06	2.95e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—lung cancer	5.89e-06	2.94e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—lung cancer	5.81e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTP1—lung cancer	5.65e-06	2.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—lung cancer	5.57e-06	2.79e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—lung cancer	5.57e-06	2.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—lung cancer	5.57e-06	2.79e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—lung cancer	5.52e-06	2.76e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAT—lung cancer	5.5e-06	2.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—lung cancer	5.49e-06	2.75e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—lung cancer	5.49e-06	2.75e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—lung cancer	5.25e-06	2.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—lung cancer	5.19e-06	2.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—lung cancer	5.12e-06	2.56e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—lung cancer	5.12e-06	2.56e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—lung cancer	5.12e-06	2.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—lung cancer	5.04e-06	2.52e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—lung cancer	5e-06	2.5e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—lung cancer	5e-06	2.5e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—lung cancer	5e-06	2.5e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—lung cancer	4.95e-06	2.48e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—lung cancer	4.95e-06	2.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—lung cancer	4.95e-06	2.48e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—lung cancer	4.93e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1A1—lung cancer	4.92e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—lung cancer	4.88e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ERCC2—lung cancer	4.88e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—lung cancer	4.73e-06	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—lung cancer	4.73e-06	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—lung cancer	4.73e-06	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—lung cancer	4.67e-06	2.33e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—lung cancer	4.53e-06	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—lung cancer	4.53e-06	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—lung cancer	4.53e-06	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—lung cancer	4.47e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOA1—lung cancer	4.22e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—lung cancer	4.18e-06	2.09e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—lung cancer	4.18e-06	2.09e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—lung cancer	4.18e-06	2.09e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—lung cancer	4.12e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—lung cancer	3.85e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—POMC—lung cancer	3.67e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CREBBP—lung cancer	3.57e-06	1.79e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—lung cancer	3.39e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—lung cancer	3.34e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—lung cancer	2.95e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—lung cancer	2.93e-06	1.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—lung cancer	2.55e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—EP300—lung cancer	2.43e-06	1.22e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—lung cancer	1.8e-06	9e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—lung cancer	1.47e-06	7.35e-06	CbGpPWpGaD
